Robert F. Kennedy Jr., the controversial U.S. Health Secretary known for anti-vaccine views, is urging the FDA to reverse its 2023 decision to restrict access to more than a dozen injectable peptide treatments. These peptides, which lack clinical evidence of efficacy, were reclassified due to significant safety risks and are no longer permitted to be compounded by pharmacies for human use. Despite this, they remain widely available through black and gray markets, often marketed for "research use only." Kennedy, calling himself a "big fan" of the substances, claimed on Joe Rogan's podcast on February 27 that he used peptides to treat injuries with "really good effect." He also pledged to end what he described as the FDA's "war on peptides." While some peptide-based drugs like insulin and GLP-1s for diabetes and obesity are FDA-approved and scientifically validated, the ones Kennedy supports are not. They are frequently promoted by wellness influencers and biohackers who assert—without proof—that the compounds can reverse aging, enhance appearance, or cure diseases. The FDA's 2023 move was intended to curb the spread of unverified and potentially dangerous treatments as unregulated use surged.
When Robert F. Kennedy Jr. says he's seen "really good effect" from unproven peptides, he's not just sharing a personal health choice—he's signaling a shift toward legitimizing treatments rejected for safety risks. This blurs the line between medical regulation and celebrity-endorsed biohacking, where anecdote overrides evidence. For global health tech, especially in regions with growing digital wellness markets, this sets a dangerous precedent: if influential figures can overturn drug policy based on personal belief, the integrity of regulatory science is at risk. Nigerian startups in telemedicine or health tech must watch this closely—any erosion of trust in approved medicine could fuel demand for unregulated digital health products.
